What is CJC-1295 (No DAC) + GHRP-6?
Our molecular dataset records this blend under the synonym Mod-GRF(1-29) and GHRP-6 blend with no CAS number, formula, molecular weight or sequence, and carries no separate entry for either component. No chemistry figures are therefore quoted here; those values appear on the lot-matched certificate of analysis.
The first component, CJC-1295 without the DAC group, is a modified analogue of the amino-terminal releasing factor fragment, its substitutions chosen to resist dipeptidyl peptidase 4 cleavage while leaving the molecule short-acting, which is what the no DAC designation signals. The second, GHRP-6, is one of the original synthetic growth hormone releasing peptides, developed out of opioid peptide chemistry and later found to act at the receptor now known as the ghrelin receptor.
The rationale for combining them is that they engage separate receptors on the same cell population. In pituitary preparations a releasing factor analogue at the GHRH receptor and a secretagogue at GHS-R1a together produce a larger secretory response than either alone, an interaction repeatedly reported in animal and cell work. GHRP-6 is also noted for appetite-related signalling through the same receptor. How the interaction scales across species and preparations is not settled.
Reconstitution & handling
Sterile or bacteriostatic water is the usual diluent for a co-lyophilized blend. Add the water slowly against the vial wall and swirl until the cake is fully clear, allowing extra standing time because the larger component dissolves more slowly. Concentration should be calculated and recorded for each component separately, from its own labelled mass over the shared diluent volume.
Storage & stability
Keep the sealed vial at -20 °C, desiccated and away from light. Reconstituted blend belongs at 2 to 8 °C in single-use aliquots, without repeated freezing. A mixture inherits the stricter of its components' requirements, so handle the vial to the standard of the more fragile peptide. Prepare working solutions close to the time of use.
How it's tested
Release testing resolves the two components chromatographically. Reversed-phase HPLC at 214 and 220 nm gives a separate purity figure per peak, and mass spectrometry confirms each identity against the theoretical mass calculated for that component. Net peptide content is reported per component so the labelled fill of each can be verified. The lot-matched certificate of analysis carries the chromatogram, spectra and per-component content figures.